Search

301 Result(s)
Sort by

empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
FDA-Fast-Track-chronic-kidney-disease

FDA-Fast-Track-chronic-kidney-disease

FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Interview with Michael Schmelmer

Interview with Michael Schmelmer

"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
empulse-trial-benefit-acute-heart-failure

empulse-trial-benefit-acute-heart-failure

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
Jens Barthelmes

Jens Barthelmes

My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
Global mobility

Global mobility

We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
Niha Agarwalla

Niha Agarwalla

My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
George Okafo

George Okafo

My career challenge at Boehringer Ingelheim by George Okafo. Read it now!
Questions and Answers

Questions and Answers

Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
EMPRISE-interim-analysis

EMPRISE-interim-analysis

Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Results for Jardiance EMPACT-MI phase III trial

Results for Jardiance EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack